Atypical Absence Seizure

Merck announced that the U.S. Food and Drug Administration (FDA) has approved two supplemental new drug applications (sNDA's) for SAPHRIS® (asenapine) sublingual tablets to expand the product's indications. SAPHRIS is now indicated for the treatment of s

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion today announced that Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent indicated for the treatment of adult patients with schizophrenia, is now available.

Sunovion Pharmaceuticals Inc. (Sunovion) announced that Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent indicated for the treatment of adult patients with schizophrenia, is now available by prescription in pharmacies across th

The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGA® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age. The efficacy of INVEGA® to treat schizophrenia in adolescents was es

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion announced that data were presented from a new pooled analysis on weight and metabolic parameters across short and long-term studies in adult patients with schizophrenia treated with Latuda.